SecBot SecBot

PMVP

PMV Pharmaceuticals, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001699382 Biotech & Drug Discovery
$1.20 −0.07 (−5.91%)
Oct 26 4:00 PM ET · prev $1.27
Market cap
$98.5M
Micro cap
Consensus
Buy
92% Buy or better · 12 analysts
Median target
$4.00
+235% · range $3.00–5.00
Next earnings
Nov 5
in 10 days · EPS est. −$0.34
1 year
−24.4%
from $1.58 · Oct 27
30 days
−12.1%
from $1.36
52-week range
$1.02–1.80
−34% from high · low Feb 5
Avg volume 20D
821.8K
Oct 2 spike 3.74M
Short interest
2.79M
≈3.7% of shares · −4.3%
Days to cover
3.6
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BULLISH 7 reports · 90 days
Balance 2 bearish · 4 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 3/7 ·Next Earnings date, Nov 5, 2026
Strongest BULLISH PMV Pharmaceuticals appointed Dr. Matthew Eckler to its Board of Directors, with the press release also…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBEARISH

    Q2 2026: 1 added (0 new), 6 trimmed or exited.

  • AnalystsBULLISH

    11 of 12 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.353 → −$0.340 over 90 days. 1 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest −4.3% to 2.79M shares. 3.6 days to cover, ≈3.7% of shares.

  • TrendDOWNTREND

    13% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
ROYAL BANK OF CANADANEAR_EXIT76—
ADAGE CAPITAL PARTNERS GP, L.L.C.ADD2,360,000$3.2M
MARSHALL WACE, LLPTRIM321,610$431.0K
JACOBS LEVY EQUITY MANAGEMENT, INCTRIM70,504$94.5K
MORGAN STANLEYNEAR_EXIT41,684$55.9K
JANE STREET GROUP, LLCTRIM40,207$53.9K
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIOTRIM10,200$13.7K
MORGAN STANLEYDOUBLED864,311$1.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 92% rate it Buy or better
Strong Buy4Buy7Hold1Sell0Strong Sell0
12-month targets · 5 analysts

Price is below the lowest target. Median implies +235%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Sep 4, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
May 13, 2026Oppenheimer
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Oct 1, 2026
Eckler Matthew Joseph
Director
AWARD84,000 sh
Jun 4, 2026
BAUM CHARLES M
Director
AWARD42,000 sh
Jun 4, 2026
FLOWERS KIRSTEN
Director
AWARD42,000 sh
Jun 4, 2026
Gallagher Carol Giltner
Director
GIFT42,000 sh
Jun 4, 2026
Gallagher Carol Giltner
Director
AWARD42,000 sh
Jun 4, 2026
LEVINE ARNOLD J
Director
AWARD42,000 sh
Jun 4, 2026
Stelzer Laurie
Director
AWARD42,000 sh
Mar 5, 2026
Carulli Michael
Chief Financial Officer
AWARD240,000 sh

Earnings setup

Estimates
Nov 5
reports in 10 days
−$0.34
EPS estimate, this quarter
+4%
estimate change, 90 days
1↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.34-$0.41–-$0.25+3.8%$0.00
Next Q-$0.29-$0.36–-$0.18+17.8%$0.00
Current FY-$1.28-$1.42–-$1.03+15.3%$0.00
Next FY-$0.97-$1.15–-$0.61+11.6%$5.0M

Short side

FINRA· Sep 30, 2026
2,794,327
shares short
-4.3%
vs prior settlement
3.6
days to cover
≈3.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 5, 2026 SEC
PMV Pharmaceuticals appointed Dr. Matthew Eckler to its Board of Directors, with the press release also announcing the…
8-K — Impact 6/10
Oct 1, 2026 Insider
Eckler Matthew Joseph was granted 84,000 shares
Director
Sep 15, 2026 Short interest report
Short Interest: PMVP up 29% to 2.9M shares
Settlement 2026-09-15 | Days to cover: 2.34 | ≈3.87% of shares outstanding (est.)
Aug 31, 2026 Press
PMV Pharmaceuticals priced a dilutive underwritten public offering of 22,055,000 common shares plus pre-funded…
Impact 8/10
Aug 31, 2026 SEC
PMV Pharmaceuticals announced updated interim Phase 2 data for rezatapopt in platinum-resistant/refractory ovarian…
8-K — Impact 7/10
Aug 31, 2026 Press
PMV Pharma commences an underwritten public offering of common stock, pre-funded warrants, and warrants. The offering…
Impact 6/10
Aug 14, 2026 SEC
PMV Pharma reported Q2 2026 results with a net loss of $18.1M ($-0.34/share), beating consensus estimates of $-0.38…
8-K — Impact 5/10
Jun 30, 2026 Inst.
ROYAL BANK OF CANADA — NEAR_EXIT
76 shares (—)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
PMVP Q3 2026 Earnings Scheduled — 2026-11-05
Recent
Sep 15, 2026
Short interest
Short Interest: PMVP up 29% to 2.9M shares
Settlement 2026-09-15 | Days to cover: 2.34 | ≈3.87% of shares outstanding (est.)
Aug 31, 2026
Offering
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology…
Aug 31, 2026
Offering
PMV Pharma Announces Proposed Public Offering of Securities
PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology…
Aug 31, 2026
FDA
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology…
Aug 14, 2026
Earnings
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
PRINCETON, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology…

SecBot reports

7 filings · 4 press releases · 4 bullish · 0 bearish · 3 neutral
All PMVP filing & press-release reports (11)